Enfusion, Inc. (NYSE:ENFN) General Counsel Sells $19,289.10 in Stock

Enfusion, Inc. (NYSE:ENFN) General Counsel Matthew Campobasso sold 1,695 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $19,289.10. Following the sale, the general counsel now directly owns 70,946 shares of the company’s stock, valued at $807,365.48. This represents a 2.33 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Matthew Campobasso also recently made the following trade(s):

• On Monday, March 3rd, Matthew Campobasso sold 1,081 shares of Enfusion stock. The shares were sold at an average price of $11.48, for a total value of $12,409.88.
• On Tuesday, January 7th, Matthew Campobasso sold 976 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total value of $9,886.88.

Enfusion Stock Performance

NYSE ENFN opened at $11.24 on Monday. The stock has a fifty day moving average of $10.98 and a 200-day moving average of $9.90. The stock has a market capitalization of $1.44 billion, a P/E ratio of 280.95, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80.

Enfusion (NYSE:ENFN) last released its earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $52.94 million during the quarter, compared to analyst estimates of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. Equities research analysts forecast that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ENFN. KLP Kapitalforvaltning AS bought a new position in shares of Enfusion in the 4th quarter worth $75,000. Harbor Capital Advisors Inc. boosted its position in shares of Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after purchasing an additional 1,315 shares during the last quarter. Millennium Management LLC bought a new position in shares of Enfusion in the 4th quarter worth $114,000. Dark Forest Capital Management LP bought a new position in shares of Enfusion in the 4th quarter worth $128,000. Finally, Man Group plc bought a new position in shares of Enfusion in the 4th quarter worth $131,000. 81.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Stifel Nicolaus raised their price target on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Finally, Piper Sandler raised their price target on Enfusion from $10.00 to $11.50 and gave the company a “neutral” rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Enfusion currently has a consensus rating of “Hold” and a consensus target price of $11.13.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.